Lilly Expands Gate Bioscience Deal to Over $870 Million
Lilly adds a target to its Gate Bioscience molecular gates collaboration, with total potential value above $870M. What is and is not disclosed.
Lilly adds a target to its Gate Bioscience molecular gates collaboration, with total potential value above $870M. What is and is not disclosed.
CSL pays $355M upfront in a partnership with Alentis to co-develop lixudebart for rare kidney and liver diseases, worth up to about $1.6B.
Everest Medicines’ application to make Velsipity locally in China won priority review; production is anticipated in 2027 at about 50 million tablets a year.
Six drones hit Kusum Healthcare's Sumy plant in Ukraine, killing an engineer; co-founder Sanjeev Gupta says it could stay shut for one to two years.
A boiler explosion at the TIL Healthcare plant in Sri City, Andhra Pradesh on 3 October left several workers dead and injured; cause under investigation.
Maharashtra FDA cancelled the drug sale and distribution licences of Cipla Pune Wadki warehouse on 1 October over alleged lapses. Cipla calls it disappointing.
FDA extended its denecimig review as manufacturing-site remediation continues. No efficacy or safety issues were cited; Novo now expects a US launch in H1 2027.
Bayer will invest $2.2 billion in a New Albany, Ohio pharmaceutical campus with about 600 permanent jobs; the first module is due by 2031.
Datroway ivonescimab trials will start with a Phase III in first-line triple-negative breast cancer in a new AstraZeneca, Daiichi Sankyo and Summit pact.
Novartis Abogen deal: Abogen gets $575 million upfront and up to $7.2 billion in milestones for ABO2203, an mRNA T-cell engager for autoimmune disease.